Table 5.
Active | Placebo | |||||
---|---|---|---|---|---|---|
Baseline | Month 3 | Month 6 | Baseline | Month 3 | Month 6 | |
WC (cm) | 98.6 ± 9.0 | 96.1± 9.7 # | 95.0 ± 10.2 *#† | 101.8 ± 11.1 | 99.4 ± 11.1 # | 99.8 ± 11.2# |
HC (cm) | 112.8 ± 7.2 | 110.5 ± 8.0 # | 109.7 ± 8.1 *#† | 114.7 ± 7.3 | 112.6 ± 6.8# | 112.5 ± 7.05 # |
Weight (kg) | 85.5 ± 10.3 | 82.7 ± 10.5 *#† | 81.9 ± 10.9 *#† | 87.8 ± 13.4 | 86.1 ± 14.0 # | 85.83 ± 14.02 # |
Weight loss (%) | −3.3 ± 3.7 #† | −4.2 ± 5.2 #*† | −2.1 ± 3.4 | −2.3 ± 4.0 # | ||
BMI (kg/m2) | 28.8 ± 1.4 | 28.0 ± 1.8 #† | 27.7 ± 2.1 *#† | 28.9 ± 1.2 | 28.4 ± 1.6 # | 28.3 ± 1.7 # |
Lean Mass (kg) | 51.0 ± 9.1 | 50.0 ± 8.0 | 50.1 ± 8.3 | 52.9 ± 11.6 | 52.7 ± 11.6 | 52.8 ± 11.7 |
FM (kg) | 32.5 ± 6.3 | 30.6 + 6.7 # | 29.9 ± 7.0 # | 33.2 ± 8.0 | 31.5 ± 8.3 # | 31.0 ± 8.5 # |
FM Arm (kg) | 3.9 ± 1.2 | 3.7 ± 0.9 | 3.7 ± 1.0 | 3.8 ± 1.0 | 3.6 ± 1.0 | 3.6 ± 1.0 |
FM Leg (kg) | 12.2 ± 3.2 | 11.7 ± 3.1 | 11.8 ± 3.9 # | 12.4 ± 3.9 | 11.4 ± 4.0 | 11.4 ± 3.7 # |
FM abdominal (trunk) (kg) | 15.6 ± 3.5 | 14.4 ± 3.8 # | 14.0 ± 3.8 *#† | 16.2 ± 4.5 | 15.3 ± 4.6 # | 15.1 ± 4.6 # |
Android Fat (kg) | 3.6 ± 2.0 | 2.6 ± 1.1 # | 2.5 ± 1.0 # | 3.8 ± 2.0 | 3.1 ± 1.5 | 3.0 ± 1.5 # |
Gynoid Fat (kg) | 7.3 ± 3.8 | 5.4 ± 1.5 # | 5.3 ± 1.6 # | 7.5 ± 3.7 | 6.1 ± 3.0 # | 6.1 ± 3.0 # |
Visceral Fat (g) | 662.2 ± 207.6 | 641.6 ± 234.8 # | 596.0 ± 229.8 *#† | 686.3 ± 251.2 | 637.1 ± 261.4 | 628.9 ± 260.1 # |
Visceral Fat Area (cm2) | 125.1 ± 41.6 | 116.3 ± 49.4 | 107.6 ± 43.6 | 124.7 ± 51.0 | 112.4 ± 47.9 | 111.4 ± 47.1 |
Subcutaneous Fat (kg) | 14.9 ± 3.4 | 13.8 ± 3.6 #† | 13.5 ± 3.6 *#† | 15.6 ± 4.3 | 14.8 ± 4.5 | 14.6 ± 4.5 # |
# Indicates significant decrease from baseline (p < 0.05); * indicates significant difference in between groups in ITT analysis (p < 0.05); † indicates significant difference between groups in PP analysis (p < 0.05); WC = waist circumference; HC = hip circumference; BMI = body mass index; FM = fat mass.